Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

  • Torres Esquius, Sara|||0000-0001-7540-7284
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Romey, Marcel
  • Teule, Alex|||0000-0003-0028-7200
  • Llort, Gemma|||0000-0001-9987-7862
  • Herrero, Ana
  • Sánchez-Henarejos, Pilar
  • Vallmajó, Anna
  • González-Santiago, Santiago|||0000-0002-4787-0236
  • Chirivella, Isabel|||0000-0002-0733-3276
  • Cano, Juana María|||0000-0002-2493-0988
  • Graña, Begoña|||0000-0003-2008-8188
  • Simonetti, Sara|||0000-0003-2406-030X
  • Díaz de Corcuera, Isabel
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Sanz, Judit
  • Serrano, Sara
  • Otero, Andrea
  • Churruca, Cristina
  • Sánchez-Heras, Ana Beatriz|||0000-0003-1742-5374
  • Servitja, Sonia|||0000-0001-6988-4519
  • Guillén-Ponce, Carmen
  • Brunet, Joan|||0000-0003-1945-3512
  • Denkert, Carsten
  • Serra, Violeta|||0000-0001-6620-1065
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
IMPORTANCE RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C/D could guide therapeutic decision-making and improve survival. OBJECTIVE To characterize the clinical and tumor characteristics of germline RAD51C/D PV carriers, including the evaluation of HRD status. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study included 91 index patients plus 90 relatives carrying germline RAD51C/D PV (n = 181) in Spanish hospitals from January 1, 2014, to December 31, 2021. Genomic and functional HRD biomarkers were assessed in untreated breast and ovarian tumor samples (n = 45) from June 2022 to February 2023. MAIN OUTCOMES AND MEASURES Clinical and pathologic characteristics were assessed using descriptive statistics. Genomic HRD by genomic instability scores, functional HRD by RAD51, and gene-specific loss of heterozygosity were analyzed. Associations between HRD status and tumor subtype, age at diagnosis, and gene-specific loss of heterozygosity in RAD51C/D were investigated using logistic regression or the t test. RESULTS A total of 9507 index patients were reviewed, and 91 patients (1.0%) were found to carry a PV in RAD51C/D; 90 family members with a germline PV in RAD51C/D were also included. A total of 157 of carriers (86.7%) were women and 181 (55.8%) had received a diagnosis of cancer, mainly breast cancer or ovarian cancer. The most prevalent PVs were c.1026+5_1026+7del (11 of 56 [19.6%]) and c.709C.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Staniszewska, Anna D.
  • Domènech-Vivó, Joanna|||0000-0002-8049-7488
  • García-Galea, Eduardo|||0000-0003-4699-0786
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Pedretti, Flaminia
  • Domènech, Heura
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Arenas, Enrique
  • Verdaguer, Helena|||0000-0001-6163-382X
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Talbot, Sara
  • Tobalina, Luis
  • Leo, Elisabetta
  • Lau, Alan|||0000-0003-1055-9812
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Diez, Orland|||0000-0001-7339-0570
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Forment, Josep V.|||0000-0002-7797-2583
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Albertella, Mark Robert
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
Background: Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is sufficient to cause synthetic lethality in tumors with homologous recombination deficiency (HRD), PARP1 selective inhibitors such as saruparib (AZD5305) are being developed. It is expected that selective PARP1 inhibition leads to a safer profile that facilitates its combination with other DNA damage repair inhibitors. Here, we aimed to characterize the antitumor activity of AZD5305 in patient-derived preclinical models compared to the first-generation PARP1/2 inhibitor olaparib and to identify mechanisms of resistance. Methods: Thirteen previously characterized patient-derived tumor xenograft (PDX) models from breast, ovarian, and pancreatic cancer patients harboring germline pathogenic alterations in BRCA1, BRCA2, or PALB2 were used to evaluate the efficacy of AZD5305 alone or in combination with carboplatin or an ataxia telangiectasia and Rad3 related (ATR) inhibitor (ceralasertib) and compared it to the first-generation PARPi olaparib. We performed DNA and RNA sequencing as well as protein-based assays to identify mechanisms of acquired resistance to either PARPi. Results: AZD5305 showed superior antitumor activity than the first-generation PARPi in terms of preclinical complete response rate (75% vs. 37%). The median preclinical progression-free survival was significantly longer in the AZD5305-treated group compared to the olaparib-treated group (.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells-Roca, Laia
  • Gutierrez Enriquez, Sara
  • Bonache Real, Sandra
  • Carrasco López, Estela
  • Aza-Carmona, Miriam
  • Montalban Canudas, Gemma
  • Cruz Zambrano, Cristina
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Bogliolo, Massimo
Breast cancer; Cancer genetics, Cáncer de mama; Genética del cáncer, Càncer de mama; Genètica del càncer, The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A > G) diagnosed at age 33 with FA after a hypertoxic reaction to chemotherapy during breast cancer treatment. After DNA damage, patient cells displayed intermediate chromosome fragility, reduced survival, cell cycle defects, and significantly decreased RAD51 foci formation. With a newly developed cell-based flow cytometric assay, we measured single BRCA2 allele contributions to HRR, and found that expression of the missense allele in a BRCA2 KO cellular background partially recovered HRR activity. Our data suggest that a hypomorphic BRCA2 allele retaining 37–54% of normal HRR function can prevent FA clinical phenotype, but not the early onset of breast cancer and severe hypersensitivity to chemotherapy.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes

  • Moles Fernandez, Alejandro
  • Domènech Vivó, Joanna
  • Tenés Felipe, Anna
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
  • Gutierrez Enriquez, Sara
Cancer hereditario de mama y ovario; Pseudoexones; Variantes intrónicas profundas spliceogénicas, Càncer hereditari de mama i d'ovari; Pseudoexons; Variants intròniques profundes spliceogèniques, Hereditary breast ovarian cancer; Pseudoexons; Spliceogenic deep intronic variants, The contribution of deep intronic splice-altering variants to hereditary breast and ovarian cancer (HBOC) is unknown. Current computational in silico tools to predict spliceogenic variants leading to pseudoexons have limited efficiency. We assessed the performance of the SpliceAI tool combined with ESRseq scores to identify spliceogenic deep intronic variants by affecting cryptic sites or splicing regulatory elements (SREs) using literature and experimental datasets. Our results with 233 published deep intronic variants showed that SpliceAI, with a 0.05 threshold, predicts spliceogenic deep intronic variants affecting cryptic splice sites, but is less effective in detecting those affecting SREs. Next, we characterized the SRE profiles using ESRseq, showing that pseudoexons are significantly enriched in SRE-enhancers compared to adjacent intronic regions. Although the combination of SpliceAI with ESRseq scores (considering ∆ESRseq and SRE landscape) showed higher sensitivity, the global performance did not improve because of the higher number of false positives. The combination of both tools was tested in a tumor RNA dataset with 207 intronic variants disrupting splicing, showing a sensitivity of 86%. Following the pipeline, five spliceogenic deep intronic variants were experimentally identified from 33 variants in HBOC genes. Overall, our results provide a framework to detect deep intronic variants disrupting splicing., This research was funded by the Spanish Instituto de Salud Carlos III (ISCIII) funding an initiative of the Spanish Ministry of Economy and Innovation, partially supported by European Regional Development FEDER Funds, grant numbers PI16/01218 and PI19/01303. AM-F contract is supported by the award ERAPERMED2019-215 granted by AECC FC and by ISCIII thorough AES 2019, both within the ERAPerMed framework”. J.D.-V. contract is supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia and the European Social Fund.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

  • Romey, Marcel
  • Llort, Gemma
  • Torres-Esquius, Sara
  • Llop-Guevara, Alba
  • Gutiérrez-Enríquez, Sara
  • Teule, Alex
  • Balmaña, Judith
  • Serra, Violeta
Prevalence; Homologous recombination deficiency; Breast cancer, Prevalença; Deficiència de recombinació homòloga; Càncer de mama, Prevalencia; Deficiencia de recombinación homóloga; Cáncer de mama, Importance RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C/D could guide therapeutic decision-making and improve survival. Objective To characterize the clinical and tumor characteristics of germline RAD51C/D PV carriers, including the evaluation of HRD status. Design, Setting, and Participants This retrospective cohort study included 91 index patients plus 90 relatives carrying germline RAD51C/D PV (n = 181) in Spanish hospitals from January 1, 2014, to December 31, 2021. Genomic and functional HRD biomarkers were assessed in untreated breast and ovarian tumor samples (n = 45) from June 2022 to February 2023. Main Outcomes and Measures Clinical and pathologic characteristics were assessed using descriptive statistics. Genomic HRD by genomic instability scores, functional HRD by RAD51, and gene-specific loss of heterozygosity were analyzed. Associations between HRD status and tumor subtype, age at diagnosis, and gene-specific loss of heterozygosity in RAD51C/D were investigated using logistic regression or the t test. Results A total of 9507 index patients were reviewed, and 91 patients (1.0%) were found to carry a PV in RAD51C/D; 90 family members with a germline PV in RAD51C/D were also included. A total of 157 of carriers (86.7%) were women and 181 (55.8%) had received a diagnosis of cancer, mainly breast cancer or ovarian cancer. The most prevalent PVs were c.1026+5_1026+7del (11 of 56 [19.6%]) and c.709C>T (9 of 56 [16.1%]) in RAD51C and c.694C>T (20 of 35 [57.1%]) in RAD51D. In untreated breast cancer and ovarian cancer, the prevalence of functional and genomic HRD was 55.2% (16 of 29) and 61.1% (11 of 18) for RAD51C, respectively, and 66.7% (6 of 9) and 90.0% (9 of 10) for RAD51D. The concordance between HRD biomarkers was 91%. Tumors with the same PV displayed contrasting HRD status, and age at diagnosis did not correlate with the occurrence of HRD. All breast cancers retaining the wild-type allele were estrogen receptor positive and lacked HRD. Conclusions and Relevance In this cohort study of germline RAD51C/D breast cancer and ovarian cancer, less than 70% of tumors displayed functional HRD, and half of those that did not display HRD were explained by retention of the wild-type allele, which was more frequent among estrogen receptor–positive breast cancers. Understanding which tumors are associated with RAD51C/D and HRD is key to identify patients who can benefit from targeted therapies, such as PARP (poly [adenosine diphosphate–ribose] polymerase) inhibitors., This work was funded by Fundación SEOM (Dr Balmaña), Asociación Española de Cáncer de Mama Metastásico (Premio M. Chiara Giorgetti to Dr Balmaña), ERA-Net (RAD51predict, ERAPERMED2019-215 to Dr Serra), Asociación Española Contra el Cáncer (LABAE16020PORTT to Dr Serra and INVES20095LLOP to Dr Llop-Guevara) and LaCaixa Foundation and European Institute of Innovation and Technology/Horizon 2020 (CaixaImpulse grant LCF/TR/CC19/52470003 to Dr Llop-Guevara). Dr Gutiérrez-Enríquez received funding from Spanish Instituto de Salud Carlos III with European Regional Development FEDER Funds (PI19/01303 and PI22/01200); and resources from the Government of Catalonia (2021SGR01112).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects

  • Li, Na
  • Zethoven, Magnus
  • McInerny, Simone
  • Devereux, Lisa
  • Huang, Yu-Kuan
  • Thio, Niko
  • Gutierrez Enriquez, Sara
  • Moles Fernandez, Alejandro
  • Diez Gibert, Orland
Càncer de mama; Genètica del càncer; Mutació, Cáncer de mama; Genética del cáncer; Mutación, Breast cancer; Cancer genetics; Mutation, Bi-allelic loss-of-function (LoF) variants in the base excision repair (BER) gene NTHL1 cause a high-risk hereditary multi-tumor syndrome that includes breast cancer, but the contribution of heterozygous variants to hereditary breast cancer is unknown. An analysis of 4985 women with breast cancer, enriched for familial features, and 4786 cancer-free women revealed significant enrichment for NTHL1 LoF variants. Immunohistochemistry confirmed reduced NTHL1 expression in tumors from heterozygous carriers but the NTHL1 bi-allelic loss characteristic mutational signature (SBS 30) was not present. The analysis was extended to 27,421 breast cancer cases and 19,759 controls from 10 international studies revealing 138 cases and 93 controls with a heterozygous LoF variant (OR 1.06, 95% CI: 0.82–1.39) and 316 cases and 179 controls with a missense variant (OR 1.31, 95% CI: 1.09–1.57). Missense variants selected for deleterious features by a number of in silico bioinformatic prediction tools or located within the endonuclease III functional domain showed a stronger association with breast cancer. Somatic sequencing of breast cancers from carriers indicated that the risk associated with NTHL1 appears to operate through haploinsufficiency, consistent with other described low-penetrance breast cancer genes. Data from this very large international multicenter study suggests that heterozygous pathogenic germline coding variants in NTHL1 may be associated with low- to moderate- increased risk of breast cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents

  • Casartelli, Chiara
  • Tommasi, Chiara
  • Lazzarin, Alessandro
  • Corianò, Matilde
  • Tornali, C.
  • Serra, Olga
  • Gutiérrez-Enríquez, Sara
  • Llop-Guevara, Alba
  • Serra, Violeta
Gene function; DNA, Función genética; ADN, Funció genètica; ADN, This work was supported by European Society for Medical Oncology to BP (no grant number) and ERA-NET Cofund [ERAPERMED 2019–215 to VS].
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods

  • Jain, Shantanu
  • Bakolitsa, Constantina|||0000-0002-6980-9831
  • Brenner, Steven E.
  • Radivojac, Predrag
  • Moult, John
  • Repo, Susanna
  • Hoskins, Roger A.
  • Andreoletti, Gaia
  • Barsky, Daniel
  • Chellapan, Ajithavalli
  • Chu, Hoyin
  • Dabbiru, Navya
  • Kollipara, Naveen K.
  • Ly, Melissa
  • Neumann, Andrew J.
  • Pal, Lipika R.
  • Odell, Eric
  • Pandey, Gaurav
  • Peters-Petrulewicz, Robin C.
  • Srinivasan, Rajgopal
  • Yee, Stephen F.
  • Yeleswarapu, Sri Jyothsna
  • Zuhl, Maya
  • Adebali, Ogun
  • Patra, Ayoti
  • Beer, Michael A.
  • Hosur, Raghavendra
  • Peng, Jian
  • Bernard, Brady M.
  • Berry, Michael
  • Dong, Shengcheng
  • Boyle, Alan P.
  • Adhikari, Aashish
  • Chen, Jingqi
  • Hu, Zhiqiang
  • Wang, Robert
  • Wang, Yaqiong
  • Miller, Maximilian
  • Wang, Yanran
  • Bromberg, Yana
  • Turina, Paola
  • Capriotti, Emidio|||0000-0002-2323-0963
  • Han, James J.
  • Ozturk, Kivilcim
  • Carter, Hannah
  • Babbi, Giulia|||0000-0002-9816-4737
  • Bovo, Samuele
  • Di Lena, Pietro
  • Martelli, Pier Luigi|||0000-0002-0274-5669
  • Savojardo, Castrense
  • Casadio, Rita
  • Cline, Melissa S.
  • De Baets, Greet
  • Bonache, Sandra|||0000-0002-7395-8143
  • Diez, Orland|||0000-0001-7339-0570
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Fernández, Alejandro
  • Montalban, Gemma|||0000-0002-6958-4759
  • Ootes, Lars
  • Özkan, Selen|||0000-0002-7398-1351
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • Riera, Casandra
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Diekhans, Mark|||0000-0002-0430-0989
  • Huwe, Peter J.
  • Wei, Qiong
  • Xu, Qifang
  • Dunbrack, Roland L.
  • Gotea, Valer|||0000-0001-7857-3309
  • Elnitski, Laura
  • Margolin, Gennady
  • Fariselli, Piero
  • Kulakovskiy, Ivan V.
  • Makeev, V.J.|||0000-0001-9405-9748
  • Penzar, Dmitry D.
  • Vorontsov, Ilya E.
  • Favorov, A.V.
  • Forman, Julia R.
  • Hasenahuer, Marcia
  • Fornasari, Maria S.
  • Parisi, Gustavo|||0000-0001-7444-1624
  • Avsec, Ziga
  • Çelik, Muhammed H.
  • Nguyen, Thi Yen Duong
  • Gagneur, Julien|||0000-0002-8924-8365
  • Shi, Fang-Yuan
  • Edwards, Matthew D.|||0000-0002-3573-0025
  • Guo, Yuchun
  • Tian, Kevin
  • Zeng, Haoyang
  • Gifford, David K.
  • Göke, Jonathan
  • Zaucha, Jan|||0000-0003-3289-4590
  • Gough, Julian
  • Ritchie, Graham R.S.
  • Frankish, Adam|||0000-0002-4333-628X
  • Mudge, Jonathan M.
  • Harrow, Jennifer
  • Young, Erin L.
  • Yu, Yao|||0000-0002-2727-1746
  • Huff, Chad D.
  • Murakami, Katsuhiko
  • Nagai, Yoko
  • Imanishi, Tadashi
  • Mungall, Christopher J.
  • Jacobsen, Julius O.B.
  • Kim, Dongsup
  • Jeong, Chan-Seok
  • Jones, David T.
  • Li, Mulin Jun
  • Guthrie, Violeta Beleva
  • Bhattacharya, Rohit
  • Chen, Yun-Ching
  • Douville, Christopher
  • Fan, Jean
  • Kim, Dewey
  • Masica, David
  • Niknafs, Noushin
  • Sengupta, Sohini
  • Tokheim, Collin
  • Turner, Tychele N.
  • Yeo, Hui Ting Grace|||0000-0002-8920-8208
  • Karchin, Rachel
  • Shin, Sunyoung
  • Welch, Rene
  • Keles, Sunduz
  • Li, Yue
  • Kellis, Manolis
  • Corbi-Verge, Carles
  • Strokach, Alexey V.
  • Kim, Philip M.
  • Klein, Teri E.|||0000-0001-5527-6475
  • Mohan, Rahul
  • Sinnott-Armstrong, Nicholas A.
  • Wainberg, Michael
  • Kundaje, Anshul|||0000-0003-3084-2287
  • Gonzaludo, Nina
  • Mak, A.C.Y.
  • Chhibber, Aparna
  • Lam, Hugo Y.K.
  • Dahary, Dvir|||0000-0002-0974-8037
  • Fishilevich, S.
  • Lancet, Doron
  • Lee, Insuk
  • Bachman, Benjamin
  • Katsonis, Panagiotis
  • Lua, Rhonald C.
  • Wilson, Stephen J.
  • Lichtarge, Olivier
  • Bhat, Rajendra R.
  • Sundaram, Laksshman
  • Viswanath, Vivek
  • Bellazzi, Riccardo
  • Nicora, Nicora
  • Rizzo, Ettore
  • Limongelli, Ivan
  • Mezlini, Aziz M.
  • Chang, Ray
  • Kim, Serra
  • Lai, Carmen
  • O'Connor, Robert
  • Topper, Scott
  • van den Akker, Jeroen
  • Zhou, Alicia Y.
  • Zimmer, Anjali D.
  • Mishne, Gilad
  • Bergquist, Timothy R.
  • Breese, Marcus R.
  • Guerrero, Rafael F.|||0000-0002-8451-3609
  • Jiang, Yuxiang
  • Kiga, Nikki
  • Li, Biao
  • Mort, Matthew
  • Pagel, Kymberleigh A.
  • Pejaver, Vikas
  • Stamboulian, Moses H.
  • Thusberg, Janita
  • Mooney, Sean D.
  • Teerakulkittipong, Nuttinee|||0000-0002-2172-9277
  • Cao, Chen
  • Kundu, Kunal
  • Yin, Yizhou
  • Yu, Chen-Hsin
  • Kleyman, Michael
  • Lin, Chiao-Feng
  • Stackpole, Mary
  • Mount, Stephen M.
  • Eraslan, Gökcen
  • Mueller, Nikola S.
  • Naito, Tatsuhiko
  • Rao, Aliz R.
  • Azaria, Johnathan R.
  • Brodie, Aharon
  • Ofran, Yanay
  • Garg, Aditi
  • Pal, Debnath
  • Hawkins-Hooker, Alex
  • Kenlay, Henry
  • Reid, John
  • Mucaki, Eliseos J.
  • Rogan, Peter K.|||0000-0003-2070-5254
  • Schwarz, Jana M.
  • Searls, David B.
  • Lee, Gyu R.
  • Seok, Chaok
  • Krämer, Andreas
  • Shah, Sohela
  • Huang, ChengLai V.
  • Kirsch, Jack F.
  • Shatsky, Maxim
  • Cao, Yue
  • Chen, Haoran
  • Karimi, Mostafa
  • Moronfoye, Oluwaseyi
  • Sun, Yuanfei
  • Shen, Yang
  • Shigeta, Ron
  • Ford, Colby T.
  • Nodzak, Conor
  • Uppal, Aneeta
  • Shi, Xinghua
  • Joseph, Thomas
  • Kotte, Sujatha
  • Rana, Sadhna
  • Rao, Aditya
  • Saipradeep, Vangala G.
  • Sivadasan, Naveen
  • Sunderam, Uma
  • Stanke, Mario
  • Su, Andrew
  • Adzhubey, Ivan
  • Jordan, Daniel M.
  • Sunyaev, Shamil|||0000-0001-5715-5677
  • Rousseau, Frederic
  • Schymkowitz, Joost
  • Van Durme, Joost
  • Tavtigian, Sean V.
  • Carraro, Marco
  • Giollo, Manuel
  • Tosatto, Silvio|||0000-0003-4525-7793
  • Adato, Orit|||0000-0002-2135-8947
  • Carmel, Liran|||0000-0003-0225-8550
  • Cohen, Noa E.|||0000-0002-4638-5407
  • Fenesh, Tzila
  • Holtzer, Tamar
  • Juven-Gershon, Tamar|||0000-0003-2607-5476
  • Unger, Ron
  • Niroula, Abhishek
  • Olatubosun, Ayodeji
  • Väliaho, Jouni
  • Yang, Yang
  • Vihinen, Mauno
  • Wahl, Mary E.
  • Chang, Billy
  • Chong, Ka C.
  • Hu, Inchi
  • Sun, Rui
  • Wu, William Ka Ke|||0000-0002-5662-5240
  • Xia, Xiaoxuan
  • Zee, Benny C.
  • Wang, Maggie Haitian|||0000-0003-1223-4595
  • Wang, Meng
  • Wu, Chunlei
  • Lu, Yutong
  • Chen, Ken
  • Yang, Yuedong
  • Yates, Christopher M.
  • Kreimer, Anat
  • Yan, Zhongxia
  • Yosef, Nir|||0000-0001-9004-1225
  • Zhao, Huying
  • Wei, Zhipeng
  • Yao, Zhaomin
  • Fengfeng, Zhou
  • Folkman, Lukas|||0000-0002-5811-8875
  • Zhou, Yaoqi
  • Daneshjou, Roxana|||0000-0001-7988-9356
  • Altman, Russ B.
  • Inoue, Fumitaka
  • Ahituv, Nadav
  • Arkin, Adam P.
  • Lovisa, Federica
  • Bonvini, Paolo
  • Bowdin, Sarah
  • Gianni, Stefano
  • Mantuano, Elide
  • Minicozzi, Velia
  • Novak, Leonore
  • Pasquo, Alessandra
  • Pastore, Annalisa|||0000-0002-3047-654X
  • Petrosino, Maria
  • Puglisi, Rita
  • Toto, Angelo
  • Veneziano, Liana
  • Chiaraluce, Roberta
  • Ball, Mad P.
  • Bobe, Jason R.
  • Church, George M.
  • Consalvi, Valerio
  • Cooper, David N.|||0000-0002-8943-8484
  • Buckley, Bethany A.
  • Sheridan, Molly B.
  • Cutting, Garry R.
  • Scaini, Maria Chiara|||0000-0002-9583-3034
  • Cygan, Kamil J.
  • Fredericks, Alger M.
  • Glidden, David T.
  • Neil, Christopher
  • Rhine, Christy L.|||0000-0002-5758-5543
  • Fairbrother, William G.
  • Alontaga, Aileen Y.
  • Fenton, Aron W.
  • Matreyek, Kenneth|||0000-0001-9149-551X
  • Starita, Lea M.
  • Fowler, Douglas M.
  • Löscher, Britt-Sabina
  • Franke, Andre|||0000-0003-1530-5811
  • Adamson, Scott I.
  • Graveley, Brenton R.
  • Gray, Joe W.
  • Malloy, Mary J.
  • Kane, John P.
  • Kousi, Maria
  • Katsanis, Nicholas
  • Schubach, Max
  • Kircher, Martin
  • Mak, Angel C.Y.
  • Tang, Paul L.F.
  • Kwok, Pui-Yan
  • Lathrop, Richard H.
  • Clark, Wyatt T.
  • Yu, Guoying K.
  • LeBowitz, Jonathan H.
  • Benedicenti, Francesco|||0000-0002-9458-0688
  • Bettella, Elisa
  • Bigoni, Stefania
  • Cesca, Federica
  • Mammi, Isabella
  • Marino-Buslje, Cristina|||0000-0002-6564-1920
  • Milani, Donatella
  • Peron, Angela|||0000-0002-1769-6548
  • Polli, Roberta
  • Sartori, Stefano
  • Stanzial, Franco
  • Toldo, Irene
  • Turolla, Licia
  • Aspromonte, Maria Cristina|||0000-0002-4937-6952
  • Bellini, Mariagrazia
  • Leonardi, Emanuela|||0000-0001-8486-8461
  • Liu, Xiaoming|||0000-0001-8285-5528
  • Marshall, Christian
  • McCombie, W. Richard
  • Elefanti, Lisa
  • Menin, Chiara
  • Meyn, M. Stephen
  • Murgia, Alessandra
  • Nadeau, Kari C.Y.
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Pirooznia, Mehdi|||0000-0002-4210-6458
  • Potash, James B.
  • Dimster-Denk, Dago F.
  • Rine, Jasper D.
  • Sanford, Jeremy R.
  • Snyder, Michael|||0000-0003-0784-7987
  • Cote, Atina G.
  • Sun, Song
  • Verby, Marta W.
  • Weile, Jochen
  • Roth, Frederick P.
  • Tewhey, Ryan
  • Sabeti, Pardis C.
  • Campagna, Joan
  • Refaat, Marwan M.
  • Wojciak, Julianne
  • Grubb, Soren
  • Schmitt, Nicole
  • Shendure, Jay
  • Spurdle, Amanda B.
  • Stavropoulos, Dimitri J.
  • Walton, Nephi A.
  • Zandi, Peter P.
  • Ziv, Elad
  • Burke, Wylie
  • Chen, Flavia
  • Carr, Lawrence R.
  • Martinez, Selena
  • Paik, Jodi
  • Harris-Wai, Julie
  • Yarborough, Mark|||0000-0001-8188-4968
  • Fullerton, Stephanie M.
  • Koenig, Barbara A.
  • McInnes, Gregory
  • Shigaki, Dustin
  • Chandonia, John-Marc
  • Furutsuki, Mabel
  • Kasak, Laura|||0000-0003-4182-2396
  • Yu, Changhua
  • Chen, Rui
  • Friedberg, Iddo
  • Getz, Gad A.
  • Cong, Qian
  • Kinch, Lisa N.
  • Zhang, Jing
  • Grishin, Nick V.
  • Voskanian, Alin
  • Kann, Maricel G.
  • Tran, Elizabeth
  • Ioannidis, Nilah M.
  • Hunter, Jesse M.
  • Udani, Rupa
  • Cai, Binghuang
  • Morgan, Alexander A.
  • Sokolov, Artem
  • Stuart, Joshua M.|||0000-0002-2171-565X
  • Minervini, Giovanni|||0000-0001-7013-5785
  • Monzon, Alexander M.
  • Batzoglou, Serafim
  • Butte, Atul J.
  • Greenblatt, Marc S.
  • Hart, Reece K.
  • Hernandez, Ryan
  • Hubbard, Tim J.P.
  • Kahn, Scott
  • O'Donnell-Luria, Anne|||0000-0001-6418-9592
  • Ng, Pauline C.
  • Shon, John
  • Veltman, Joris
  • Zook, Justin M.|||0000-0003-2309-8402
Background: The Critical Assessment of Genome Interpretation (CAGI) aims to advance the state-of-the-art for computational prediction of genetic variant impact, particularly where relevant to disease. The five complete editions of the CAGI community experiment comprised 50 challenges, in which participants made blind predictions of phenotypes from genetic data, and these were evaluated by independent assessors. Results: Performance was particularly strong for clinical pathogenic variants, including some difficult-to-diagnose cases, and extends to interpretation of cancer-related variants. Missense variant interpretation methods were able to estimate biochemical effects with increasing accuracy. Assessment of methods for regulatory variants and complex trait disease risk was less definitive and indicates performance potentially suitable for auxiliary use in the clinic. Conclusions: Results show that while current methods are imperfect, they have major utility for research and clinical applications. Emerging methods and increasingly large, robust datasets for training and assessment promise further progress ahead.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

  • Romey, Marcel
  • Llort, Gemma
  • Torres-Esquius, Sara
  • Llop-Guevara, Alba
  • Gutiérrez-Enríquez, Sara
  • Teule, Alex
  • Balmaña, Judith
  • Serra, Violeta
Prevalence; Homologous recombination deficiency; Breast cancer, Prevalença; Deficiència de recombinació homòloga; Càncer de mama, Prevalencia; Deficiencia de recombinación homóloga; Cáncer de mama, Importance RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C/D could guide therapeutic decision-making and improve survival. Objective To characterize the clinical and tumor characteristics of germline RAD51C/D PV carriers, including the evaluation of HRD status. Design, Setting, and Participants This retrospective cohort study included 91 index patients plus 90 relatives carrying germline RAD51C/D PV (n = 181) in Spanish hospitals from January 1, 2014, to December 31, 2021. Genomic and functional HRD biomarkers were assessed in untreated breast and ovarian tumor samples (n = 45) from June 2022 to February 2023. Main Outcomes and Measures Clinical and pathologic characteristics were assessed using descriptive statistics. Genomic HRD by genomic instability scores, functional HRD by RAD51, and gene-specific loss of heterozygosity were analyzed. Associations between HRD status and tumor subtype, age at diagnosis, and gene-specific loss of heterozygosity in RAD51C/D were investigated using logistic regression or the t test. Results A total of 9507 index patients were reviewed, and 91 patients (1.0%) were found to carry a PV in RAD51C/D; 90 family members with a germline PV in RAD51C/D were also included. A total of 157 of carriers (86.7%) were women and 181 (55.8%) had received a diagnosis of cancer, mainly breast cancer or ovarian cancer. The most prevalent PVs were c.1026+5_1026+7del (11 of 56 [19.6%]) and c.709C>T (9 of 56 [16.1%]) in RAD51C and c.694C>T (20 of 35 [57.1%]) in RAD51D. In untreated breast cancer and ovarian cancer, the prevalence of functional and genomic HRD was 55.2% (16 of 29) and 61.1% (11 of 18) for RAD51C, respectively, and 66.7% (6 of 9) and 90.0% (9 of 10) for RAD51D. The concordance between HRD biomarkers was 91%. Tumors with the same PV displayed contrasting HRD status, and age at diagnosis did not correlate with the occurrence of HRD. All breast cancers retaining the wild-type allele were estrogen receptor positive and lacked HRD. Conclusions and Relevance In this cohort study of germline RAD51C/D breast cancer and ovarian cancer, less than 70% of tumors displayed functional HRD, and half of those that did not display HRD were explained by retention of the wild-type allele, which was more frequent among estrogen receptor–positive breast cancers. Understanding which tumors are associated with RAD51C/D and HRD is key to identify patients who can benefit from targeted therapies, such as PARP (poly [adenosine diphosphate–ribose] polymerase) inhibitors., This work was funded by Fundación SEOM (Dr Balmaña), Asociación Española de Cáncer de Mama Metastásico (Premio M. Chiara Giorgetti to Dr Balmaña), ERA-Net (RAD51predict, ERAPERMED2019-215 to Dr Serra), Asociación Española Contra el Cáncer (LABAE16020PORTT to Dr Serra and INVES20095LLOP to Dr Llop-Guevara) and LaCaixa Foundation and European Institute of Innovation and Technology/Horizon 2020 (CaixaImpulse grant LCF/TR/CC19/52470003 to Dr Llop-Guevara). Dr Gutiérrez-Enríquez received funding from Spanish Instituto de Salud Carlos III with European Regional Development FEDER Funds (PI19/01303 and PI22/01200); and resources from the Government of Catalonia (2021SGR01112).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects

  • Li, Na
  • Zethoven, Magnus
  • McInerny, Simone
  • Devereux, Lisa
  • Huang, Yu-Kuan
  • Thio, Niko
  • Gutierrez Enriquez, Sara
  • Moles Fernandez, Alejandro
  • Diez Gibert, Orland
Càncer de mama; Genètica del càncer; Mutació, Cáncer de mama; Genética del cáncer; Mutación, Breast cancer; Cancer genetics; Mutation, Bi-allelic loss-of-function (LoF) variants in the base excision repair (BER) gene NTHL1 cause a high-risk hereditary multi-tumor syndrome that includes breast cancer, but the contribution of heterozygous variants to hereditary breast cancer is unknown. An analysis of 4985 women with breast cancer, enriched for familial features, and 4786 cancer-free women revealed significant enrichment for NTHL1 LoF variants. Immunohistochemistry confirmed reduced NTHL1 expression in tumors from heterozygous carriers but the NTHL1 bi-allelic loss characteristic mutational signature (SBS 30) was not present. The analysis was extended to 27,421 breast cancer cases and 19,759 controls from 10 international studies revealing 138 cases and 93 controls with a heterozygous LoF variant (OR 1.06, 95% CI: 0.82–1.39) and 316 cases and 179 controls with a missense variant (OR 1.31, 95% CI: 1.09–1.57). Missense variants selected for deleterious features by a number of in silico bioinformatic prediction tools or located within the endonuclease III functional domain showed a stronger association with breast cancer. Somatic sequencing of breast cancers from carriers indicated that the risk associated with NTHL1 appears to operate through haploinsufficiency, consistent with other described low-penetrance breast cancer genes. Data from this very large international multicenter study suggests that heterozygous pathogenic germline coding variants in NTHL1 may be associated with low- to moderate- increased risk of breast cancer.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents

  • Casartelli, Chiara
  • Tommasi, Chiara
  • Lazzarin, Alessandro
  • Corianò, Matilde
  • Tornali, C.
  • Serra, Olga
  • Gutiérrez-Enríquez, Sara
  • Llop-Guevara, Alba
  • Serra, Violeta
Gene function; DNA, Función genética; ADN, Funció genètica; ADN, This work was supported by European Society for Medical Oncology to BP (no grant number) and ERA-NET Cofund [ERAPERMED 2019–215 to VS].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells-Roca, Laia
  • Gutierrez Enriquez, Sara
  • Bonache Real, Sandra
  • Carrasco López, Estela
  • Aza-Carmona, Miriam
  • Montalban Canudas, Gemma
  • Cruz Zambrano, Cristina
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Bogliolo, Massimo
Breast cancer; Cancer genetics, Cáncer de mama; Genética del cáncer, Càncer de mama; Genètica del càncer, The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A > G) diagnosed at age 33 with FA after a hypertoxic reaction to chemotherapy during breast cancer treatment. After DNA damage, patient cells displayed intermediate chromosome fragility, reduced survival, cell cycle defects, and significantly decreased RAD51 foci formation. With a newly developed cell-based flow cytometric assay, we measured single BRCA2 allele contributions to HRR, and found that expression of the missense allele in a BRCA2 KO cellular background partially recovered HRR activity. Our data suggest that a hypomorphic BRCA2 allele retaining 37–54% of normal HRR function can prevent FA clinical phenotype, but not the early onset of breast cancer and severe hypersensitivity to chemotherapy.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes

  • Moles Fernandez, Alejandro
  • Domènech Vivó, Joanna
  • Tenés Felipe, Anna
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
  • Gutierrez Enriquez, Sara
Cancer hereditario de mama y ovario; Pseudoexones; Variantes intrónicas profundas spliceogénicas, Càncer hereditari de mama i d'ovari; Pseudoexons; Variants intròniques profundes spliceogèniques, Hereditary breast ovarian cancer; Pseudoexons; Spliceogenic deep intronic variants, The contribution of deep intronic splice-altering variants to hereditary breast and ovarian cancer (HBOC) is unknown. Current computational in silico tools to predict spliceogenic variants leading to pseudoexons have limited efficiency. We assessed the performance of the SpliceAI tool combined with ESRseq scores to identify spliceogenic deep intronic variants by affecting cryptic sites or splicing regulatory elements (SREs) using literature and experimental datasets. Our results with 233 published deep intronic variants showed that SpliceAI, with a 0.05 threshold, predicts spliceogenic deep intronic variants affecting cryptic splice sites, but is less effective in detecting those affecting SREs. Next, we characterized the SRE profiles using ESRseq, showing that pseudoexons are significantly enriched in SRE-enhancers compared to adjacent intronic regions. Although the combination of SpliceAI with ESRseq scores (considering ∆ESRseq and SRE landscape) showed higher sensitivity, the global performance did not improve because of the higher number of false positives. The combination of both tools was tested in a tumor RNA dataset with 207 intronic variants disrupting splicing, showing a sensitivity of 86%. Following the pipeline, five spliceogenic deep intronic variants were experimentally identified from 33 variants in HBOC genes. Overall, our results provide a framework to detect deep intronic variants disrupting splicing., This research was funded by the Spanish Instituto de Salud Carlos III (ISCIII) funding an initiative of the Spanish Ministry of Economy and Innovation, partially supported by European Regional Development FEDER Funds, grant numbers PI16/01218 and PI19/01303. AM-F contract is supported by the award ERAPERMED2019-215 granted by AECC FC and by ISCIII thorough AES 2019, both within the ERAPerMed framework”. J.D.-V. contract is supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia and the European Social Fund.